Globus Medical Rises to Record High as Leerink Upgrades
(Bloomberg) -- Globus Medical rises as much as 4.9% to a record high after Leerink analyst Richard Newitter upgraded to outperform from market perform and raised PT $40 from $29, saying the company is set to stage its strongest growth rebound yet.
- Sees negative-to-positive growth transition in 1H, with a return to double-digits in 2H and 2018
- Estimates 14% of organic rev. growth acceleration for 4Q16-2Q18 period
- Sees a return to growth for the company’s "core spine" division and $10m incremental rev. contribution in 2H from new product areas like robotics and trauma
- Says co.’s EV/Ebitda multiple is below those of peers despite a much higher margin profile
- Notes the stock has seen two major growth acceleration periods previously but the ensuing re- acceleration should also be steeper
- Stock has 5 buys, 7 holds, 1 sell, avg PT $30: Bloomberg data
- Shares rose ~24% YTD, while the S&P 500 health equipment index gained 13%
To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net To contact the editors responsible for this story: Arie Shapira at ashapira3@bloomberg.net Sebastian Silva
Alert:
HALISTER1Source: BFW (Bloomberg First Word)
Tickers GMED US (Globus Medical Inc)
People Richard Newitter (Leerink Partners LLC)
To de-activate this alert, click
hereTo modify this alert, click
hereUUID: 7947283